Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Diffuse large B cell lymphoma; Lymphomatoid granulomatosis; Lymphoproliferative disorders; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 27 Apr 2018 Planned initiation date changed from 5 Apr 2018 to 3 May 2018.
- 26 Apr 2018 Status changed from not yet recruiting to recruiting.
- 02 Apr 2018 Planned initiation date changed from 30 Mar 2018 to 5 Apr 2018.